Trichostatin A (TSA)

製品コードS1045

Trichostatin A (TSA)化学構造

分子量(MW):302.4

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

サイズ 価格(税別)  
JPY 41002.00
JPY 74202.00
JPY 144420.00

カスタマーフィードバック(6)

  • Gck expression in WT primary hepatocytes transduced with FOXO1 and KR-FOXO1 adenoviruses in the presence or absence of trichostatinA (TSA).

    Cell, 2017, 171(4):824-835.e18. Trichostatin A (TSA) purchased from Selleck.

    Effect of TSA, SAHA and silibinin alone and in combination on left panel: IF staining for p-histone H3 Ser 10 and p-MPM-2 Ser /Thr positive cells and a-tubulin for mitotic spindle and DAPI as nuclear stain in H1299 cells. Right panel: % positive p-histone H3 Ser 10 mitotic cells and expression of p-MPM-2 Ser /Thr protein levels in H1299 cells.

    Epigenetics 2012 7(10):1161-72. Trichostatin A (TSA) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

  • (B) The mRNA level of PRRT2 in the presence of different concentrations of DAC and TSA.

    Biochem Biophys Res Commun, 2017, 485(2):454-460. Trichostatin A (TSA) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM TSA was added.

     

     

    2010 Dr. Zhang of Tianjin Medical University. Trichostatin A (TSA) purchased from Selleck.

製品安全説明書

HDAC阻害剤の選択性比較

生物活性

製品説明 Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
ターゲット
HDAC [1]
(Cell-free assay)
~1.8 nM
体外試験

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 MnPGSpVv[3Srb36gRZN{[Xl? NU[zXXh{OC55zszN NETqN2EzPGh? NITZSGFmfGijbn;s NUj3fod7\W6qYX7j[ZMhTU6jQzDhZ4V1gWyjdHnvckBidmRiaX7jdoVie2W|IFXOZWMh[WK3bnThcoNmKGmwIITo[UB1d3SjbDDj[YxtKGy7c3H0[UBidmRiYYSgeIhmKGOnbHygd5Vz\mGlZR?= Mn\6NlU4QDdyN{m=
TE13 M4HidWZ2dmO2aX;uJGF{e2G7 M4fVUlAvO87:TR?= M2TrOVI1cA>? NG\1SJl2eC2{ZXf1cIF1\XNiUlHTV2Y2SSCuZY\lcC=> MUmyOVU4QTZ4NR?=
TE13 NHvUfo9CeG:ydH;zbZMhSXO|YYm= M{HnSVAvO87:TR?= NXrmVpJ4OjSq M2C3folvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25? MnTQNlU2Pzl4NkW=
MEFs M2\NcGZ2dmO2aX;uJGF{e2G7 NFPIcow2|ryP MmHTNVZp MV;pcoNz\WG|ZYOgeIhmKEWSRVOgZZR1[WOqbXXueEwhXGm{IHTlcIl3\XK7IHHu[EB1cGViZX\mbYNq\W6leTDv[kBx\WSnc4ThcEBnd3KvYYTpc44> NEXjbYUzPTR6Mk[zOC=>
SW480  MVvGeY5kfGmxbjDBd5NigQ>? MXSwMlHPxE1? MYG0PIg> NWLB[VQ3TE2VTx?= M2XjN5JmfmW{c3XzJGVOXA>? MkPKNlU1OzR7OUe=
PC3  M3flT2Z2dmO2aX;uJGF{e2G7 NXzCc2lZOC5zzszN MV20PIg> MX\EUXNQ MlT1doV3\XK|ZYOgSW1V NHrFOlIzPTR|NEm5Oy=>
SW480  NEfYUIdHfW6ldHnvckBCe3OjeR?= MlrRNE4y|ryP MX60PIg> MlzQSG1UVw>? M1jEcoF1fGWwdXH0[ZMhcW64YYPpc44h[W6mIH3p[5JifGmxbh?= NUPOWm5{OjV2M{S5PVc>
PC3  Mn20SpVv[3Srb36gRZN{[Xl? MnP5NE4y|ryP MkX2OFhp M3XGR2ROW09? NX\pNYFt[XS2ZX71ZZRmeyCrbo\hd4lwdiCjbnSgcYloemG2aX;u NYDuSYhxOjV2M{S5PVc>
SW480  M130VGZ2dmO2aX;uJGF{e2G7 Ml7sNE4y|ryP MoTaOFhp MXPEUXNQ M3;jdYlv\HWlZYOgbY5kemWjc3Wgc4YhUESDQ{GgZY5lKEiGQVOyJI9vKFOudXeg[4Vv\XNicILvcY91\XJ? NHH5fZczPTR|NEm5Oy=>
PC3  NIi4NYRHfW6ldHnvckBCe3OjeR?= NHvIZnIxNjIQvF2= M1L2dFQ5cA>? MWjEUXNQ MYfpcoR2[2W|IHnuZ5Jm[XOnIH;mJGhFSUNzIHHu[EBJTEGFMjDvckBUdHWpIHflcoV{KHC{b33veIVz MYKyOVQ{PDl7Nx?=
A431 MXnBdI9xfG:|aYOgRZN{[Xl? NVfZcYRSOi9zMD:1NE8yODCwTR?= NYTsbldiPDiq MVzEUXNQ MUHpcohq[mm2czD0bIUh[2WubDDndo94fGh? MoPHNlU{PzFyNkm=
A431 NUC5V4hLTnWwY4Tpc44hSXO|YYm= MW[1NI5O NGLiNJozNzZxMUKvNlRp NUjRO4ZpTE2VTx?= M3fH[YFkfGm4YYTld{BxOjFiYX7kJIlvcGmkaYTzJGFVTjNiZYjwdoV{e2mxbh?= MUmyOVM4OTB4OR?=
MDA-MB-231 NWL4TXF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWL2PWVNOC14MEDuUS=> NV3ON5Q2OjSq MYjEUXNQ MmezTWM2OCCxZjCxNFBvVQ>? MoDENlUyQTJ5MkG=
MCF7 NWjEfJhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIToSXMxNTZyMH7N MXGyOIg> M3rWZ2ROW09? NFWxOXRKSzVyIH;mJFc2dk1? MlK5NlUyQTJ5MkG=
SKOV-3 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;SOFAyNTFyzszN MlLCNlRp M{LPR2ROW09? M3\PeGlEPTBib3[gOU43|ryP M4nYeFI2OTZ7NEmx
A549 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXVO44yNTFyzszN MYGyOIg> MUDEUXNQ NUHH[3BwUUN3MDDv[kA{NjMQvF2= MXyyOVE3QTR7MR?=
SKOV-3 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWe4XYRiOC5zLUJOwG0> MXy0PIg> MnvSSG1UVw>? M1TJeGlEPTBib3[gNE44|ryP NYTWcopNOjVzNkm0PVE>
A549 NWXMPYlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrDSZExNjFvMd88US=> NW\s[JptPDiq NUjMUWpnTE2VTx?= MUHJR|UxKG:oIECuNljPxE1? MknNNlUyPjl2OUG=
SKOV-3 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHr0XYoxNjBzLUCuPe69VQ>? MVy3Nog> NWTa[W5GTE2VTx?= M3vtdmlEPTBib3[gNE4{Os7:TR?= MYKyOVE3QTR7MR?=
A549 NEDKVGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fmXFAvODFvMD65{txO Ml\XO|Jp MlPYSG1UVw>? NFX6SYFKSzVyIH;mJFAvODcQvF2= NFvycIszPTF4OUS5NS=>
HeLa NHS0PWNHfW6ldHnvckBCe3OjeR?= MXyyOVBvVQ>? NUKxcIdwOT[q M1nLUGROW09? MnrtbY5kemWjc3XzJGN[WDGDMTDtVm5CKGW6cILld5Nqd28EoB?= M4XuT|I2OTF4Nki4
CNE2 NFjFephIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTMdHVlOTByLU[wNI5O MWWyOE81QC95Mni= NXe3fXpQcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTD0bY1mNSCjbnSg[I9{\S2mZYDlcoRmdnRibXHucoVz MmCwNlQ6Pjl7MEG=
PC3 NFnjZY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYKxNFAuOTByMH7N MlnuNlRp NIPFZndKSzVyIH;mJFMxOG6P NUny[YZtOjR6NUS2OVg>
LNCaP MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITiPVIyODBvMUCwNI5O M{P1PFI1cA>? NGDFe5BKSzVyIH;mJFMxOG6P NXzPfHNZOjR6NUS2OVg>
HeLa  M33CdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXWy{txO NYnndFBxPDiq M2Kx[4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDhZo92fCB{NTW= NFjTW2ozPDh2NkGzOS=>
HMEC-1  M1fiZ2Z2dmO2aX;uJGF{e2G7 MkfMN|Axdk1? NXrxWW9ROjSq MV;pcoNz\WG|ZYOg[ZhxemW|c3nvckBw\sLiVlXHSnI{yqCvUl7B M3[ycFI1PzFyNkOx
HeLa NF7qcYdHfW6ldHnvckBCe3OjeR?= NVLENnJoOW2P NF7VRlAxNjWq NXXGOoVD[WKxbHnzbIV{KHSqZTD0c5RidCCKRFHDJIFkfGm4aYT5 MWGyOFcxPzR5NB?=
ACP02 NEn0U2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPQNlUxNzN3MD:1NFBvVQ>? M171[VI1cA>? MkO5[IVkemWjc3XzJINmdGxidnnhZoltcXS7IH;mJIFxeHKxeHntZZRmdHliN{FCpEUh[XRiMkWwxsBvVQ>? MoX4NlQ3Pjh3NEe=
ACP03 Mmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{joWlI2OC9|NUCvOVAxdk1? MofrNlRp Morl[IVkemWjc3XzJINmdGxidnnhZoltcXS7IH;mJIFxeHKxeHntZZRmdHliN{FCpEUh[XRiMkWwxsBvVQ>? NI\DclgzPDZ4OEW0Oy=>
U87 GBM MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLrNVAxNzNyMD:1NFAhdk1? NYX6O5pOPzJiaB?= MVyxNFAmKGW2aHHuc4w> NX\aWm81emWmdXPld{Bu\WGwIHPlcIwhdnWvYnXyJIJ6KDNzLDC1OEwh[W6mIEW4xsAm NIWxTG0zPDR4NEi0NS=>
U87 GBM NXj5UlJ3TnWwY4Tpc44hSXO|YYm= NH;yS3kyODBxNUCwJG5u M2e1ZlQ5KGh? NInwTmIyODBnIHX0bIFvd2x? M{jkfmlv\HWlZYOgV4Vv\XOlZX7j[U1NcWunIFHseIVz[XSrb37zJIlvKE63Y3zlZZIhVW:{cHjvcI9ogQ>? M1viZlI1PDZ2OESx
RPE NYHxboVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moj0NE4zNzBwND:wMlgwOSEQvF2= NFzreW0zPC92OD:3NkBp NFjSTlhFVVOR Mk\YbY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gZpkh[2WubDDjfYNt\SCjcoLld5Q> MkHaNlQ1PTZ4MEK=
HT29  M{jtWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUmxPFAhdk1? NG[0TpY4OiCq NX7LS3gzUUN3MDDv[kAyQDBibl2= MVeyOFM3QDJ4NR?=
hMSCs MU\GeY5kfGmxbjDBd5NigQ>? M4O2elYvOjVibl2= NIK3WFMzPCCq MojKSG1UVw>? M4DVT5N1[WKrbHn6[ZMhUGm|dH;u[UBC[2W2eXzheIlwdiCjbnSgeIhmKEW6cILld5Nqd25ib3[gVIx2emmyb4TlcpQhT2WwZYO= MlOwNlQ{OTJ|NU[=
Huh7  NXjxe2FpTnWwY4Tpc44hSXO|YYm= M4\NflAvOS9yLkWvNU4xKM7:TR?= NHTNRnczPGh? NEX4WoJ{fXCycnXzd4V{KFmWSFTDNkBo\W6nIHX4dJJme3Orb36= M2XkfVI1OjZ7Nkey
SKOV3 Mk\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TkcVAvODVvMjFOwG0> NGX3RmEyOC9{ND:0PEBp MontSG1UVw>? MYnt[YRq[XSnczDndo94fGhiYYLy[ZN1KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MlO5NlQzOjN6MEG=
A2780 NV7WZoVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;JVFIxNjB3LUKg{txO MVWxNE8zPC92ODDo MYLEUXNQ M1fCNY1m\GmjdHXzJIdzd3e2aDDhdpJme3RiaX6gZUBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ Mn7WNlQzOjN6MEG=
SRA01/04  M3XOWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vKZ|AvOiEQvF2= Mn7SOFghcA>? NH;LPZhFVVOR NYnETnRYe3WycILld5NmeyClZXzsJJBzd2yrZnXyZZRqd25idHjyc5VocCC|dYDwdoV{e2mwZzD0bIUhWEl|Sz;Bb5QtKHB|OF3BVGsh[W6mIFXST|EwOiC|aXfuZYxqdmdicHH0bJdigXN? NIW1N3EzPDF3N{i3PC=>
HLEB3 MmHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXSNE4zKM7:TR?= M{PQelQ5KGh? NEXsVXVFVVOR MUjzeZBxemW|c3XzJINmdGxicILvcIln\XKjdHnvckB1cHKxdXfoJJN2eHC{ZYPzbY5oKHSqZTDQTVNMN0GtdDygdFM5VUGSSzDhcoQhTVKNMT:yJJNq\26jbHnu[{Bx[XSqd3H5dy=> MkKwNlQyPTd6N{i=
SRA01/04  Ml;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zGelAvPC9yLkig{txO MmH6OFghcA>? M1noOGROW09? M{nSfolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NVjuToNZOjRzNUe4O|g>
HLEB3 MlHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mne3NE41NzBwODFOwG0> M3TuOVQ5KGh? NF;yc3NFVVOR Mkn1bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MnfpNlQyPTd6N{i=
HCT116 M4fZT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETkbokxNjJizszN MnzzNVIhcA>? NVjXOmdl\W6qYX7j[ZMh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUBz[WSrYYTpc44> NXO5S41IOjRzMkKyN|E>
CA46 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYCzM|YwOTJxMkSvOFghdk1? MYe0PEBp NI\RTlNqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHH0JFI1KGGwZDC0PEBvVcLi MkPSNlQxPjR7NUG=
PMNs Mnv0SpVv[3Srb36gRZN{[Xl? MnXHN|Ahdk1? NHrr[nQ1QCCq NXH2T3lLcW6qaXLpeJMh\W[oZYLvZ5l1d3OrczygTGRCSyCjY4Tpeol1gSCjbnSgVoFkKGGldHn2bZR6 NYPiVJBVOjN7OEi2NVc>
H1299 NYjMPHNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoS2NeKh|ryPwrC= NEfjeIEzPC92OD:3NkBp NFP0fXZmfGijbn;s NI\sOVBqdmO{ZXHz[ZMh[2WubDDk[YF1cCCjZoTldkAzPGh? NG[ybmMzOzlzNk[wPS=>
A549 M{fjdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4D5VlAvOjVxMD61M|Eh|ryP MVOyOE81QC95MjDo NVm1TI9C\XSqYX7vcC=> M2DBUolvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpckBkd26lZX70doF1cW:wIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? NUTHTXN1OjN6Nke5PVE>
H1299 M3;yNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUD6SnI3OC5{NT:wMlUwOSEQvF2= MoHMNlQwPDhxN{KgbC=> MVzleIhidm:u NFH3V3ZqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY4h[2:wY3XueJJifGmxbjDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ MlXZNlM5Pjd7OUG=
A549 MXLBdI9xfG:|aYOgRZN{[Xl? NXG3ZZNnOC53L{Gg{txO MnPyOFghcA>? Mn7M[ZRp[W6xbB?= NE\OS4FqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NWfUd4hCOjN6Nke5PVE>
H1299 NWXjZoVSSXCxcITvd4l{KEG|c3H5 NWLxTlR2OC53L{Gg{txO NX;aZ|k1PDhiaB?= NYnGfFl2\XSqYX7vcC=> Mn7qbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NYK1PXd3OjN6Nke5PVE>
SUM149PT NWizZ|lNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDxNk84NjVxMUCg{txO MXK0PEBp MmPlSG1UVw>? MYrpcoR2[2W|IHPlcIwh\GWjdHigZZQhOiEQvF2gbY5{\W6|aYTpeoVtgQ>? NH3Pd4YzOzd7Mk[zPC=>
SUM190PT MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoSyOVAwOTByL{K1NEBvVQ>? NH7vb401QCCq NYPDU3A2TE2VTx?= NEjRcW1qdmS3Y3XzJINmdGxiZHXheIgh[XRiNUCgcm0he2Wwc3n0bZZmdHl? MkPiNlM4QTJ4M{i=
HCT1 NVf6NmJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[wMlIwOS5yL{WuNEDPxE1? MmDxNVIwOjRxM{[vOFghcA>? M3\wO4lv\HWlZYOgZ4VtdCCmZXH0bEBqdiClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy MWGyN|c4ODByMB?=
Lovo M2HyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HGUlAvOi9zLkCvOU4xKM7:TR?= MkKyNVIwOjRxM{[vOFghcA>? Mo\PbY5lfWOnczDj[YxtKGSnYYToJIlvKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= M2rJelI{PzdyMECw
AGS NUSzWmM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYOwMlAyPS1zIN88US=> M2rBR|czKGh? MV7pcoR2[2W|IHPlcIwh\GWjdHigZ49v[2WwdILheIlwdiCmZYDlcoRmdnSueR?= M{\hOlI{PzR3MEK0
Huh7 MmHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXexJO69VQ>? MoP4NlQhcA>? MlHnSG1UVw>? MnnsdoVlfWOnczDhZo92fCB{MDWgeoli[mmuaYT5xsA> NXTDclZXOjN4NEO5N|M>
ECC1 MWXGeY5kfGmxbjDBd5NigQ>? MlOwOVAxKG6P NHL3fmI2KGR? NHrnXGdFVVOR MUjpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? NWT3R2Q6OjN3M{C3Olk>
HEC1A MUTGeY5kfGmxbjDBd5NigQ>? M4KyRVUxOCCwTR?= M2n2XVUh\A>? MX3EUXNQ NHLXcXNqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= MUOyN|U{ODd4OR?=
EN1 NWHzTI1LTnWwY4Tpc44hSXO|YYm= MUm1NFAhdk1? Mmn0OUBl NGrGXnRFVVOR MnLMbY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? NWfFWnMzOjN3M{C3Olk>
MFE296 NV7WO|F2TnWwY4Tpc44hSXO|YYm= NW\TbWNnPTByIH7N MmrEOUBl M{\XVmROW09? NHTC[pdqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= NV\NTm53OjN3M{C3Olk>
HASMCs NXPtcWNSTnWwY4Tpc44hSXO|YYm= NYPO[lNXOC13MECgcm0> M2ixZ|Yh\A>? M2fHUIRwf25vcnXneYxifGW|IITo[UBmgHC{ZYPzbY9vKG:oIFjBSGMh[W6mIHPlcIwhfmmjYnnsbZR6 MonDNlM2OTh2Nke=
U373 MYjGeY5kfGmxbjDBd5NigQ>? NF3qW4QxNjJ3L{CuOU8yKM7:TR?= MlHwNlQhcA>? MmfLbY5kemWjc3XzJHBTNUJiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1RZpi\EN? MYeyN|Q4PDF5MR?=
ARN8  MX7GeY5kfGmxbjDBd5NigQ>? M2DaT|AvODVvMjFOwG0> NFTORmIzPCCq NIXVbXJz\WS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gdFU{NWSncHXu[IVvfCCpZX7ld{BjgSCQdYTsbY4uOw>? M3W1SlI{PDdyNUSw
MCF7 NIXDW4FHfW6ldHnvckBCe3OjeR?= M1XBelAvODVvMjFOwG0> NEjlNVYzPCCq MWny[YR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZicEWzMYRmeGWwZHXueEBo\W6nczDifUBPfXSuaX6tNy=> MYSyN|Q4ODV2MB?=
H1299  NGWwe21HfW6ldHnvckBCe3OjeR?= M2DSdFAvOzQkgKOxxsDDvU1? M2rHelI1NzR6IHi= M3;WemROW09? MWPpcoNz\WG|ZYOgSU1k[WSqZYLpckBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7 MmXUNlM1PjF7N{W=
H1299 NGfIWIJHfW6ldHnvckBCe3OjeR?= NY\EOJFNOC53IN88US=> NYDzW3dvPDhiaB?= MmHOSG1UVw>? NH;nVJdqdmirYnn0d{B1cGVibXnndoF1d3K7IIDveIVvfGmjbDDjc41jcW6nIIfpeIghe2muaXLpcolv NHO3R5EzOzR4MUm3OS=>
H1299 NXnR[4VFTnWwY4Tpc44hSXO|YYm= MVywMlUh|ryP MWC0PEBp NYjkNotVTE2VTx?= NUTwOJRucW6qaXLpeJMhfGinIHnueoF{cX[nbnXzd:KhKGOxbXLpcoUhf2m2aDDzbYxq[mmwaX6= M2W2c|I{PDZzOUe1
MG-63  NYrvRVZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjrNE4{KM7:TR?= NFPpc2IyOi17NjDo M1m2dGROW09? MkDHbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHPvMZRz\WG2bXXueEB4cXSqIH3leIZwem2rbh?= MojUNlM1PTF6MUe=
LM8 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX[wMlMh|ryP MXGxNk06PiCq NVHJRlN1TE2VTx?= NV7ab5F3cW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJINwNXS{ZXH0cYVvfCC5aYToJI1mfG[xcn3pci=> M4XxTFI{PDVzOEG3
K562 NWHzVmJbTnWwY4Tpc44hSXO|YYm= NI\1OXUxNjVizszN NXLqO5ZyOjRiaB?= NHLkUlBmfGijbn;s M3T0Z4Rm[3KnYYPld{B1cGViZX76fY1mKGGldHn2bZR6KG:oIFjERWN{KGOxLYTy[YF1dWWwdDD3bZRpKGO3cnP1cYlv MmP1NlM1OzB7NUe=
HEL M2jie2Z2dmO2aX;uJGF{e2G7 M3rLNFAvPSEQvF2= NGLnXXozPCCq MoTH[ZRp[W6xbB?= MYnk[YNz\WG|ZYOgeIhmKGWweont[UBi[3Srdnn0fUBw\iCKRFHDd{Bkdy22cnXheI1mdnRid3n0bEBkfXKldX3pci=> NUS0XYlbOjN2M{C5OVc>
HL60 NGiwc2tCeG:ydH;zbZMhSXO|YYm= M1;NS|Eh|ryP NIK5[IUzPCCq NXvKT2ZpcW6mdXPld:Kh[2WubDDk[YF1cA>? NWfzNmhnOjN2MEC1NVk>
KG1 MlWzRZBweHSxc3nzJGF{e2G7 M3noXlEh|ryP NYjNN4Y2OjRiaB?= MWTpcoR2[2W|wrDj[YxtKGSnYYTo MkHoNlM1ODB3MUm=
Kazumi M2PLXGFxd3C2b4Ppd{BCe3OjeR?= Mn7yNUDPxE1? MYGyOEBp NEL5UIJqdmS3Y3XzxsBk\WyuIHTlZZRp NXHLSXd7OjN2MEC1NVk>
K562 MYLBdI9xfG:|aYOgRZN{[Xl? MXWxJO69VQ>? M{XvUlI1KGh? NF\CZ2pqdmS3Y3XzxsBk\WyuIHTlZZRp M4nqRVI{PDByNUG5
THP1 M{LEPGFxd3C2b4Ppd{BCe3OjeR?= M1\uSlEh|ryP NF;jelMzPCCq M1LYeolv\HWlZYRCpINmdGxiZHXheIg> NHm1[WkzOzRyMEWxPS=>
SH-SY5Y NVXqeWgxTnWwY4Tpc44hSXO|YYm= NXTkRph3OjVyIH7N NFTZZnoyPiCq MYPjbIFv\2W|IHX4dJJme3Orb36gdIF1fGW{bjDv[kBo\W6nczDpcpZwdH[nZDDpckBkcG:uZYP0[ZJwdCC|eX70bIV{cXNuIIXweIFs\SCjbnSg[YZndHW6 NGq2VJkzOzN{NkSyNi=>
HEK293 NGf6eo5HfW6ldHnvckBCe3OjeR?= MnnMNUDDvU4EoB?= NW\FU3pCOThiaNMg M3;rTolvcGmkaYTzJJRp\SCtYXzpdolvNTdvbXXkbYF1\WRicnXjdpVqfG2nboSgc4Yhe3mwcHjpcIlvNTFiYXfndoVo[XSnczDpcpRwKGGpZ4Lld49u\XN? MViyN|I5PDh2OB?=
HTK MnnqSpVv[3Srb36gRZN{[Xl? NX3DUWdTPDByIH7N NXjGUHE3PzJiaB?= MUfpcohq[mm2czDUS2Yu|rMkgKPJcoR2[2WmIF35c4Zq[nKxYnzhd5QhTGmoZnXy[Y51cWG2aX;u NVLEPYR4OjN{OESwNFI>
HTK NVjQVINPTnWwY4Tpc44hSXO|YYm= MVyxNFAuQDBybl2= Ml;aO|IhcA>? NIf4RpZjdG:la4OgWGdHNc7{4pETTY5lfWOnZDDSU3Mh[W6mIFiyU|LDqEGlY4XteYxifGmxbh?= MYKyN|I5PDByMh?=
Caco-2  NX74OWRqTnWwY4Tpc44hSXO|YYm= MmLrNUDDvU4EoB?= MWmyOEBp M1LQe4Rm[3KnYYPld{BUTVKWIIDyc5RmcW5iZYjwdoV{e2mxbh?= MmfmNlMyQTVyN{C=
HeLa MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml2xNVAxKG6P Mn;4NlQhcA>? M{HoR2ROW09? NUnBZZZtUUN3MDDv[kAyODCwTR?= M{HlU|I{OTZ3N{S4
HeLa M1;Cemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml73OFAhdk1? MoD0OFghcA>? NXvkXmR5TE2VTx?= MnvUTWM2OCCxZjC0NI5O NXO3SpFtOjNzNkW3OFg>
HeLa MoHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfsN|YzOCCwTR?= NXLDVHZYPzJiaB?= NUfHc4R3TE2VTx?= MWnJR|UxKG:oIEKwcm0> M3rqUVI{OTZ3N{S4
HeLa MkfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTrNVAwOzBxNUCgcm0> Ml\hO|IhcA>? MoHpSG1UVw>? NGXwVotqdmO{ZXHz[ZMhfGinIH71cYJmeiCxZjDNUXAhMM7WzrjtLUBtd3O|IHPlcIx{KGSxc3Wg[IVx\W6mZX70cJk> MmrYNlMyPjV5NEi=
MDA-MB-231 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUiyOU01ODBibl2= M2LERlQ5KGh? M3PLfWlEPTBib3[gNlY{NjKwTdMg MkXINlMxPTVzOUi=
MCF-7  NEi5TGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVGwRmZpOjVvNECwJI5O MXu0PEBp NV\tNYtnUUN3MDDv[kAzOjBwNH7N MWeyN|A2PTF7OB?=
ECC-1  NV7IR|JTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{f3clExOCCwTR?= NWTDc4lmOjRiaB?= M1L4bYV1cGGwb3y= MnjTbY5kemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJIFxd3C2b4TpZ{BvfWOuZXmgeI8hOzVn M2ThVlI{ODJ6OECz
HEC-1A M{nHbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXWxNFAhdk1? Ml6xNlQhcA>? M3TWbYV1cGGwb3y= NVzkeI8{cW6lcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKGGyb4D0c5Rq[yCwdXPs[YkhfG9iM{ml NIPsS44zOzB{OEiwNy=>
NHAC-kn MmjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVL4XVFCOTBxMUCwM|UxOCCwTR?= M2fZSVEzKGh? MYXEUXNQ NXPJZWU{UUN3MDDv[kA2ODCwTR?= MWGyN|AyPzh5MR?=
A549 NWjjV4FUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrtNlUxKG6P M{XuWVYuPzJiaB?= MXfEUXNQ MWjjZZV{\XNiYTDndoVifGW{IHnubIljcXSxcomg[YZn\WO2IHPvcYJqdmVid3n0bEBVYFRib4Kg[ZJtd3Srbnni MmPqNlI6QTR5OEC=
MG-63 NELRd4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXCN|AxKG6P NIq2ZlUyOiCq NIDGWVFFVVOR MmHybY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFg3LQ>? Mk\JNlI4QTl|M{i=
MG-63 NXO3TWptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrxVYtTOzByIH7N M{nDWlI1KGh? NYjUbIluTE2VTx?= NULu[GZUcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDZ5JR?= M1v5UFIzPzl7M{O4
MG-63 NUDNb5c2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:zNFAhdk1? M{X4XlQ5KGh? MmDrSG1UVw>? NIXDVWVqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPTZn NY\LWFBLOjJ5OUmzN|g>
HL60  MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Wzd|E2OC1|NUCgcm0> NW\nWmVTOjRiaB?= M1XNUYlv[3KnYYPld{Bk\WyuIHHwc5B1d3Orc9Mge4hmdiClb37j[Y51emG2aX;ud{BpcWeqZYKgeIhidiB{NUCgcm0> MljDNlI4PTN5M{m=
U937 MnHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPKW2gyPTBvM{WwJI5O M1PSZlI1KGh? M170UYlv[3KnYYPld{Bk\WyuIHHwc5B1d3Orc9Mge4hmdiClb37j[Y51emG2aX;ud{BpcWeqZYKgeIhidiB{NUCgcm0> MX[yNlc2Ozd|OR?=
SCC-6 M{PaVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPBO4MzODBvM{KwNEBvVQ>? M1zQfVEzNzJ2L{S4JIg> MnvjSG1UVw>? MUTpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDv[kBUS0NvNjDj[YxteyCrbjDhJIRwe2VvIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? NGrkT|IzOjV3MkOyNS=>
U87  NHrzU2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvqXm1DOTByLUOwNEBv\w>? M{[1R|I1KGh? NGriU5ZqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPzJnIDDheEAzODCwZx?= MoO3NlIzPzB6NEm=
K562 NUHFdnd6TnWwY4Tpc44hSXO|YYm= NWH6O3d{OSEQvF2= NV;qdXJJOTJiaB?= M2X3d2ROW09? MXXlcohidmOnczD0bIUh\XiycnXzd4lwdiCxZjDSWW5ZOyCrbnT1Z4VlKGK7IEWtZZpiNUOmUh?= M2i4S|IzOTd7MUm4
Reh NVPBUlJjTnWwY4Tpc44hSXO|YYm= M1XnR|AvOy9zIN88US=> Ml35NVIhcA>? M3P1dGROW09? NGXkcpRmdmijbnPld{B1cGViZYjwdoV{e2mxbjDv[kBTXU6[MzDpcoR2[2WmIHL5JFUu[XqjLVPkVi=> NU\zPHNKOjJzN{mxPVg>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

In vitro HDAC activity:

Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
細胞試験:

[1]

+ 展開
  • 細胞株: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
  • 濃度: Dissolved in absolute ethanol, final concentrations ~10 μM
  • 反応時間: 96 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
  • 製剤: Dissolved in DMSO
  • 投薬量: ~5 mg/kg/day
  • 投与方法: Injection s.c.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
3mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 302.4
化学式

C17H22N2O3

CAS No. 58880-19-6
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03839758 Not yet recruiting Shoulder Arthritis Université de Montréal May 2019 Not Applicable
NCT03839758 Not yet recruiting Shoulder Arthritis Université de Montréal May 2019 Not Applicable
NCT03858517 Not yet recruiting Shoulder Arthroplasty Stryker Trauma GmbH April 2019 --
NCT03858517 Not yet recruiting Shoulder Arthroplasty Stryker Trauma GmbH April 2019 --
NCT03735173 Recruiting Arthropathy Shoulder|Shoulder Pain|Shoulder Osteoarthritis|Shoulder Arthritis|Shoulder Arthropathy Associated With Other Conditions|Necrosis of Bone|Arthritis|Inflammatory Arthritis Mayo Clinic December 1 2018 Not Applicable
NCT03735173 Recruiting Arthropathy Shoulder|Shoulder Pain|Shoulder Osteoarthritis|Shoulder Arthritis|Shoulder Arthropathy Associated With Other Conditions|Necrosis of Bone|Arthritis|Inflammatory Arthritis Mayo Clinic December 1 2018 Not Applicable

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • 回答:

    Our S1045 Trichostatin A (TSA) is R enantiomer.

HDACシグナル伝達経路

HDAC Inhibitors with Unique Features

相関HDAC製品

Tags: Trichostatin A (TSA)を買う | Trichostatin A (TSA) ic50 | Trichostatin A (TSA)供給者 | Trichostatin A (TSA)を購入する | Trichostatin A (TSA)費用 | Trichostatin A (TSA)生産者 | オーダーTrichostatin A (TSA) | Trichostatin A (TSA)化学構造 | Trichostatin A (TSA)分子量 | Trichostatin A (TSA)代理店
×

大阪市内で「G20サミット」が開催されることに伴い、大阪府内で大規模な交通規制が行われる影響で、6月26日(水)から7月1日(月)までの間、下記地域へ出荷が行えなくなります。
対象地域
大阪府(全域)、兵庫県(芦屋市、尼崎市、伊丹市、西宮市)
上記地域より西の地域につきましては納期の遅延が予想されます。
また、国際便も遅延が予想されているため国内在庫がない製品の納期が一週間程度遅れる可能性がございます。
ご不便をおかけいたしますが、宜しくお願い申し上げます。

×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID